Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Rong-Qing Li

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Related publications

The Impact of Initial Gefitinib or Erlotinib Versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Clinical Cancer Research
Cancer ResearchOncology
2012English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2020English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

ESMO Open
Cancer ResearchOncology
2016English

P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Post-Progression Survival After EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

PLoS ONE
Multidisciplinary
2015English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy